Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: Randomized-withdrawal study design

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 53, Issue 6, 2014, Pages

  Coghill, David R ^a   Banaschewski, Tobias ^b   Lecendreux, Michel ^c   Johnson, Mats ^d   Zuddas, Alessandro ^e   Anderson, Colleen S ^f   Civil, Richard ^f   Dauphin, Matthew ^f   Higgins, Nicholas ^f   Lyne, Andrew ^g   Gasior, Maria ^f   Squires, Liza A ^f  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f SHIRE   (United States)

^g Shire Pharmaceuticals   (United Kingdom)

Author keywords

attention deficit hyperactivity disorder; central nervous system stimulants; lisdexamfetamine dimesylate; maintenance of efficacy; randomized controlled trial

Indexed keywords

LISDEXAMFETAMINE; PLACEBO;

ADOLESCENT; ADOLESCENT DISEASE; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DECREASED APPETITE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT REFUSAL; VOMITING; WEIGHT REDUCTION;

EID: 84901198640     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2014.01.017     Document Type: Article

References (26)

1. M. Wolraich, L. Brown, and R.T. Brown et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/ hyperactivity disorder in children and adolescents Pediatrics 128 2011 1007 1022
2. G. Polanczyk, M.S. de Lima, B.L. Horta, J. Biederman, and L.A. Rohde The worldwide prevalence of ADHD: a systematic review and metaregression analysis Am J Psychiatry 164 2007 942 948
3. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines Third ed. 2011 CADDRA Toronto http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf Accessed July 2013
4. T. Banaschewski, D. Coghill, and P. Santosh et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline Eur Child Adolesc Psychiatry 15 2006 476 495
5. National Institute for Health and Clinical Excellence. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. London: 2009. Available at: http://www.nice.org. uk/nicemedia/live/12061/42060/42060.pdf. Accessed July 29, 2013.
6. S. Pliszka Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 46 2007 894 921
7. A.C. Childress, and F.R. Sallee The use of lisdexamfetamine dimesylate for the treatment of ADHD Expert Rev Neurother 12 2012 13 26
8. M. Pennick Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine Neuropsychiatr Dis Treat 6 2010 317 327
9. S.W. Boellner, J.G. Stark, S. Krishnan, and Y. Zhang Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study Clin Ther 32 2010 252 264
10. L.A. Adler, D.W. Goodman, and S.H. Kollins et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder J Clin Psychiatry 69 2008 1364 1373
11. J. Biederman, S.W. Boellner, A. Childress, F.A. Lopez, S. Krishnan, and Y. Zhang Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study Biol Psychiatry 62 2007 970 976
12. J. Biederman, S. Krishnan, Y. Zhang, J.J. McGough, and R.L. Findling Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study Clin Ther 29 2007 450 463
13. D.R. Coghill, T. Banaschewski, and M. Lecendreux et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder Eur Neuropsychopharmacol 23 2013 1208 1218
14. R.L. Findling, A.C. Childress, and A.J. Cutler et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/ hyperactivity disorder J Am Acad Child Adolesc Psychiatry 50 2011 395 405
15. S.B. Wigal, S.H. Kollins, A.C. Childress, and L. Squires A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder Child Adolesc Psychiatry Ment Health 3 2009 17
16. T. Wigal, M. Brams, M. Gasior, J. Gao, L. Squires, and J. Giblin Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder: novel findings using a simulated adult workplace environment design Behav Brain Funct 6 2010 34
17. M. Brams, R. Weisler, and R.L. Findling et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design J Clin Psychiatry 73 2012 977 983
18. C. Gillberg, H. Melander, and A.L. von Knorring et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial Arch Gen Psychiatry 54 1997 857 864
19. M. Rosler, R. Fischer, R. Ammer, C. Ose, and W. Retz A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder Eur Arch Psychiatry Clin Neurosci 259 2009 120 129
20. R.L. Findling, A.C. Childress, S. Krishnan, and J.J. McGough Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder CNS Spectr 13 2008 614 620
21. R. Weisler, J. Young, G. Mattingly, J. Gao, L. Squires, and L. Adler Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder CNS Spectr 14 10 2009 573 585
22. L.E. Arnold, R.L. Lindsay, and C.K. Conners et al. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder J Child Adolesc Psychopharmacol 14 2004 542 554
23. D. Michelson, J.K. Buitelaar, and M. Danckaerts et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study J Am Acad Child Adolesc Psychiatry 43 2004 896 904
24. J.K. Buitelaar, D. Michelson, and M. Danckaerts et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year Biol Psychiatry 61 2007 694 699
25. J.K. Buitelaar, G.E. Trott, and M. Hofecker et al. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD Int J Neuropsychopharmacol 15 2012 1 13
26. J. Biederman, E. Mick, and C. Surman et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder J Clin Psychopharmacol 30 2010 549 553